Survodutide

The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.

Regulatory status

Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.

The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.

Studied in human phase 2 trials for weight loss and liver disease. PepIndex does not evaluate clinical significance and does not describe administration.

• A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis — The New England journal of medicine (2024)

  Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2024).

• Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial — The lancet. Diabetes & endocrinology (2024)

  Peer-reviewed article indexed in PubMed, published in The lancet. Diabetes & endocrinology (2024).

• Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial — Diabetologia (2024)

  Peer-reviewed article indexed in PubMed, published in Diabetologia (2024).

• Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial — JACC. Heart failure (2024)

  Peer-reviewed article indexed in PubMed, published in JACC. Heart failure (2024).

• Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction — Expert opinion on investigational drugs (2024)

  Peer-reviewed article indexed in PubMed, published in Expert opinion on investigational drugs (2024).

• Survodutide Once Weekly for the Treatment of Adults with Obesity — The New England journal of medicine (2026)

  Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2026).

• Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis — Journal of hepatology (2024)

  Peer-reviewed article indexed in PubMed, published in Journal of hepatology (2024).

• Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1) — Diabetes, obesity & metabolism (2026)

  Peer-reviewed article indexed in PubMed, published in Diabetes, obesity & metabolism (2026).

PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.

No certificate records are indexed. Either none are published, or those published could not be read without an account.

How to read a certificate of analysis